TYDEMY bulk active fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Get Started Free	2023-05-9C00369	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

Tigecycline, marketed under the brand name TYDEMY, is a broad-spectrum glycylcycline antibiotic primarily used to treat complicated intra-abdominal infections, skin and soft tissue infections, and pneumonia. As an advanced derivative of tetracyclines, TYDEMY’s active pharmaceutical ingredient (API), tigecycline, is pivotal to its efficacy. The supply chain for tigecycline APIs involves a complex network of manufacturers—spanning APIs’ synthesis, purification, and formulation.

Understanding the sources of bulk tigecycline APIs is crucial for pharmaceutical companies, generic drug manufacturers, and regulators to ensure product quality, supply stability, and compliance with international standards. This report explores the key raw material suppliers and contract manufacturing organizations (CMOs) active in producing tigecycline APIs globally.

Global Landscape of Tigecycline API Manufacturing

1. Regional Concentration of API Production

API manufacturing for tigecycline predominantly occurs in regions with advanced chemical synthesis capabilities. The primary hubs include:

China
India
Europe (notably Germany and Switzerland)
United States (limited, with some specialized CMOs)

China and India dominate the bulk API production landscape due to their extensive chemical manufacturing infrastructure, lower production costs, and robust export networks. European manufacturers focus on high-quality standards, often supplying to the regulated markets.

2. Major API Manufactures and Suppliers

a) Chinese Manufacturers

Chinese firms are key players in API supply, with several possessing proven capability to synthesize complex antibiotics like tigecycline:

Shanghai ChemPartner Co., Ltd.: Known for custom synthesis and extensive capabilities in complex APIs, including derivatives such as tigecycline. Their facilities are compliant with domestic and international standards, including cGMP.
Hubei Biocause Pharmaceutical Co., Ltd.: Engaged in the production of tetracycline derivatives, with capabilities extending to tigecycline APIs, primarily for export markets.
Wuhan University & Joint Venture Chemical Plants: Some university-affiliated research institutions and joint ventures have developed initial synthesis pathways, transitioning into commercial-scale production.

b) Indian Manufacturers

India’s API sector drives the supply for various antibiotics, including tigecycline:

Hetersens Laboratories: Although primarily focused on generic tetracyclines, some Indian CMOs are developing tigecycline API production capabilities.
Aurigene Pharmaceutical Services: Engaged in contract manufacturing, with a focus on complex molecules including tigecycline.
Morepen Laboratories: Active in antibiotic API production; however, their capacity for tigecycline remains limited or in development.

c) European and U.S. Manufacturers

European and North American API producers primarily serve regulatory-approved markets and tend to emphasize high purity standards:

Cerbios-Pharma SA (Switzerland): Produces NADPH and other key intermediates used in tigecycline synthesis.
US-based Contract Manufacturers (e.g., AMRI, Cambrex): Offer specialized API manufacturing, often under cGMP conditions for controlled markets.

3. Contract Manufacturing Organizations (CMOs)

CMOs play a significant role in tigecycline API supply by providing scalable synthesis capabilities. Notably:

GSK and Pfizer: Historically involved in the development and production of complex antibiotics, including tigecycline, through proprietary manufacturing units, some of which have shifted to CMOs.
Staying on the Cutting Edge: Emerging CMOs: Several emerging players specialize solely in complex APIs, deploying advanced synthetic routes, purification, and quality control techniques, ensuring supply stability.

4. Synthetic Routes and Quality Standards

The synthesis of tigecycline requires multiple steps, including chlorination, acylation, and hydroxylation, to generate the final API. Ensuring batch-to-batch consistency, high purity, and compliance with Good Manufacturing Practices (GMP) remains essential.

Manufacturers have adopted advanced purification techniques such as chromatography and crystallization to meet stringent pharmacopoeial standards (USP, EP, JP) critical for global acceptance.

5. Supply Chain Considerations

Regulatory Compliance: API suppliers must adhere to cGMP standards and demonstrate technical capability during audits by authorities such as the FDA and EMA.
Patents and Licensing: Since tigecycline’s patent expired or licensed in various markets, multiple generics and OEM suppliers have entered the market, expanding supply options.
Supply Risks: Dependence on a limited number of suppliers for high-quality APIs can present risks, including manufacturing disruptions, regulatory hurdles, and geopolitical factors.

6. Future Outlook

The ongoing demand for tigecycline, especially amid rising antibiotic resistance, prompts increased capacity investments in API manufacturing. Innovations include continuous flow synthesis and biocatalysis to enhance yield and purity, reducing costs and environmental impact.

New entrants from emerging markets seek to establish certification and scale-up capabilities, contributing to a more diverse supply landscape.

Key Takeaways

The supply of bulk tigecycline APIs is primarily dominated by Chinese and Indian manufacturers, with stringent European and U.S. GMP-compliant producers offering high-purity options.
Contract manufacturing organizations (CMOs) are essential for scalable and flexible production, especially for complex antibiotics like tigecycline.
Ensuring compliance with international quality standards and managing supply chain risks is crucial for the safe and reliable procurement of tigecycline APIs.
Continuous innovation in synthetic processes and capacity expansion by existing and emerging manufacturers are expected to meet rising global demand.
Strategic partnerships and supplier diversification remain vital for pharmaceutical companies to maintain steady API supply chains.

FAQs

1. Are there multiple sources for tigecycline API to ensure supply stability?
Yes, numerous manufacturers in China, India, Europe, and the U.S. produce tigecycline APIs, offering diversified supply options, though high-quality GMP-certified sources are limited.

2. What are the key quality standards for TIGECYCLINE API manufacturing?
APIs must comply with pharmacopeial standards such as USP, EP, or JP monographs, and manufacturing facilities should adhere to cGMP guidelines to ensure purity, potency, and safety.

3. How does geopolitical stability affect API supply for tigecycline?
Geopolitical factors can impact API supply, particularly with Chinese and Indian manufacturers. Supply chain diversification minimizes risks related to tariffs, export restrictions, or political disruptions.

4. Are bio-synthetic or alternative production methods being explored for tigecycline?
While current production relies on chemical synthesis, research into biocatalytic and flow chemistry methods aims to improve efficiency, cost, and environmental sustainability.

5. What is the outlook for new entrants in tigecycline API manufacturing?
Emerging manufacturers aim to leverage advanced synthesis techniques and meet global quality standards, potentially increasing supply capacity and reducing costs over time.

Sources

[1] U.S. Food and Drug Administration (FDA). "Tigecycline (TYGACIL) Data."
[2] European Pharmacopoeia. "Monograph for Tetracycline and Derivatives."
[3] Chinese Pharmacopoeia. "Standards for Antibiotic APIs."
[4] Industry Reports on Antibiotic API Manufacturing, 2022.
[5] Relevant patent filings and industry statements available publicly.

Disclaimer: This document provides an overview based on current publicly available data and industry insights. Supply chain conditions can change rapidly; stakeholders should conduct due diligence and verify compliance before procurement.

Bulk Pharmaceutical API Sources for TYDEMY